Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial
{{output}}
Background: Hypothalamic obesity resulting from hypothalamic damage might affect melanocortin signalling. We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. ... ...
